| Original language | English (US) |
|---|---|
| Pages (from-to) | 2900-2903 |
| Number of pages | 4 |
| Journal | Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 9 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2021 |
ASJC Scopus subject areas
- Immunology and Allergy
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, No. 7, 07.2021, p. 2900-2903.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - COVID-19 in a series of patients with aspirin-exacerbated respiratory disease
AU - White, Andrew A.
AU - Cahill, Katherine N.
AU - Jerschow, Elina
AU - Kuruvilla, Merin
AU - Sehanobish, Esha
AU - Bensko, Jillian
AU - Laidlaw, Tanya M.
AU - Levy, Joshua M.
N1 - Funding Information: Conflicts of interest: A. A. White is on speakers bureau for Astra Zeneca, Regeneron/Sanofi, and Optinose; on Advisory Board for Genentech, Regeneron/Sanofi, Optinose, and GlaxoSmithKline; and has received grant support from Astra Zeneca. K. N. Cahill is on Advisory Board for Teva, Novartis, GlaxoSmithKline, Blueprint Medicines, Regeneron, and Sanofi-Pasteur; and has received consulting fees from Third Harmonic Bio, Novartis, and Ribon Therapeutics. E. Jerschow is on Advisory Board for GlaxoSmithKline, Sanofi-Regeneron, and Novartis/Genentech; and has received grant support from AstraZeneca and Cumberland. T. M. Laidlaw is on Advisory Board for GlaxoSmithKline, Sanofi-Genzyme, and Regeneron; and has received grant support from GlaxoSmithKline and Regeneron. J. M. Levy is on Advisory Board for Regeneron/Sanofi and GlaxoSmithKline; and has received grant support from AstraZeneca, Cumberland Pharmaceuticals, Genentech, Regeneron/Sanofi, and Optinose. No funding was received for this study. Funding Information: Conflicts of interest: A. A. White is on speakers bureau for Astra Zeneca, Regeneron/Sanofi, and Optinose; on Advisory Board for Genentech, Regeneron/Sanofi, Optinose, and GlaxoSmithKline; and has received grant support from Astra Zeneca . K. N. Cahill is on Advisory Board for Teva, Novartis, GlaxoSmithKline, Blueprint Medicines, Regeneron, and Sanofi-Pasteur; and has received consulting fees from Third Harmonic Bio, Novartis, and Ribon Therapeutics. E. Jerschow is on Advisory Board for GlaxoSmithKline, Sanofi-Regeneron, and Novartis/Genentech; and has received grant support from AstraZeneca and Cumberland . T. M. Laidlaw is on Advisory Board for GlaxoSmithKline, Sanofi-Genzyme, and Regeneron; and has received grant support from GlaxoSmithKline and Regeneron . J. M. Levy is on Advisory Board for Regeneron/Sanofi and GlaxoSmithKline; and has received grant support from AstraZeneca , Cumberland Pharmaceuticals , Genentech , Regeneron / Sanofi , and Optinose .
PY - 2021/7
Y1 - 2021/7
UR - http://www.scopus.com/inward/record.url?scp=85106366894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106366894&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2021.04.060
DO - 10.1016/j.jaip.2021.04.060
M3 - Article
C2 - 33965591
AN - SCOPUS:85106366894
SN - 2213-2198
VL - 9
SP - 2900
EP - 2903
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 7
ER -